$0.38
-0.01 (-2.69%)
Open$0.39
Previous Close$0.39
Day High$0.39
Day Low$0.37
52W High$2.49
52W Low$0.40
Volume—
Avg Volume1.98M
Market Cap48.10M
P/E Ratio—
EPS$-1.08
SectorBiotechnology
Analyst Ratings
Buy
12 analysts
Price Target
+2,025.2% upside
Current
$0.38
$0.38
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.94M | 13.90M | 54.83M |
| Net Income | -171,687,151 | -166,059,576 | 10.00M |
| Profit Margin | -1,327.4% | -1,261.0% | 18.2% |
| EBITDA | -178,333,385 | -182,070,624 | 16.80M |
| Free Cash Flow | — | — | 9.93M |
| Rev Growth | -7.0% | -7.0% | -2.4% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |